Literature DB >> 2848026

Purification and characterization of 5 beta-cholestane-3 alpha,7 alpha,12 alpha-triol 27-hydroxylase from female rat liver mitochondria.

K Okuda1, O Masumoto, Y Ohyama.   

Abstract

5 beta-Cholestane-3 alpha,7 alpha,12 alpha-triol 27-hydroxylase (5 beta-cholestane-3 alpha,7 alpha,12 alpha-triol, NADPH:oxygen oxidoreductase (26-hydroxylating), EC 1.14.13.15) was purified from female rat liver mitochondria based on its catalytic activity. The final preparation of the enzyme showed a single major band on the sodium dodecyl sulfate-polyacrylamide gel electrophoretogram. The content of purified enzyme was 12 nmol/mg of protein, and the specific activity was 431 nmol/min/mg of protein. The molecular weight of the enzyme was determined from sodium dodecyl sulfate-polyacrylamide gel electrophoresis as 52,500. The absorption spectra of the purified enzyme and that of the dithionite-reduced CO complex showed peaks at 417 and 450 nm, respectively, indicating the enzyme belongs to the cytochrome P-450 family. Upon reconstitution with the electron-transferring system of the adrenal (adrenodoxin and NADPH-adrenodoxin reductase), the enzyme showed high activity hydroxylating 5 beta-cholestane-3 alpha,7 alpha-12-triol at position 27 with a turnover number of 35.5 min-1 and Km of 6.3 microM. The enzyme activity was completely lost when the electron-transferring system was replaced by that of microsomes (NADPH-cytochrome P-450 reductase purified from rat liver microsomes), confirming that the P-450 enzyme was of the mitochondrial type, but not of the microsomal. The omission of cytochrome P-450, adrenodoxin, or NADPH-adrenodoxin reductase resulted in complete loss of enzyme activity. The specific activity toward 5 beta-cholestane-3 alpha, 7 alpha-diol was less than one-half that toward cholestanetriol and that toward cholesterol was about one-fiftieth. The enzyme showed no activity toward xenobiotics such as benzphetamine, 7-ethoxycoumarin, and benzo[a]pyrene. Its activity was not inhibited by metyrapone and slightly inhibited by aminoglutethimide. The enzyme activity was markedly lowered in an atmosphere of CO/O2/N2, 40/20/40.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2848026

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Review of progress in sterol oxidations: 1987-1995.

Authors:  L L Smith
Journal:  Lipids       Date:  1996-05       Impact factor: 1.880

2.  Conversion of 7-ketocholesterol to oxysterol metabolites by recombinant CYP27A1 and retinal pigment epithelial cells.

Authors:  Gun-Young Heo; Ilya Bederman; Natalia Mast; Wei-Li Liao; Illarion V Turko; Irina A Pikuleva
Journal:  J Lipid Res       Date:  2011-03-16       Impact factor: 5.922

Review 3.  Biosynthesis of bile acids in mammalian liver.

Authors:  S Kevresan; K Kuhajda; J Kandrac; J P Fawcett; M Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Jul-Sep       Impact factor: 2.441

4.  Posttranslational modification by an isolevuglandin diminishes activity of the mitochondrial cytochrome P450 27A1.

Authors:  Casey D Charvet; James Laird; Yunfeng Xu; Robert G Salomon; Irina A Pikuleva
Journal:  J Lipid Res       Date:  2013-03-11       Impact factor: 5.922

5.  Suppression of sterol 27-hydroxylase mRNA and transcriptional activity by bile acids in cultured rat hepatocytes.

Authors:  J Twisk; E C de Wit; H M Princen
Journal:  Biochem J       Date:  1995-01-15       Impact factor: 3.857

6.  Drugs and Scaffold That Inhibit Cytochrome P450 27A1 In Vitro and In Vivo.

Authors:  Morrie Lam; Natalia Mast; Irina A Pikuleva
Journal:  Mol Pharmacol       Date:  2017-11-30       Impact factor: 4.436

7.  Frameshift and splice-junction mutations in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis in Jews or Moroccan origin.

Authors:  E Leitersdorf; A Reshef; V Meiner; R Levitzki; S P Schwartz; E J Dann; N Berkman; J J Cali; L Klapholz; V M Berginer
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

8.  CYP46A1-dependent and independent effects of efavirenz treatment.

Authors:  Natalia Mast; Nicole El-Darzi; Alexey M Petrov; Young Li; Irina A Pikuleva
Journal:  Brain Commun       Date:  2020-10-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.